Grazoprevir/elbasvir for the immediate treatment of recently acquired HCV genotype 1 or 4 infection in MSM
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Grazoprevir/elbasvir for the immediate treatment of recently acquired HCV genotype 1 or 4 infection in MSM
Authors
Keywords
-
Journal
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2020-03-04
DOI
10.1093/jac/dkaa091
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Progression of liver fibrosis following acute hepatitis C virus infection in HIV-positive MSM
- (2019) Astrid M. Newsum et al. AIDS
- Early treatment of acute hepatitis C infection is cost-effective in HIV-infected men-who-have-sex-with-men
- (2019) Stephanie Popping et al. PLoS One
- Quantification of second generation direct-acting antivirals daclatasvir, elbasvir, grazoprevir, ledipasvir, simeprevir, sofosbuvir and velpatasvir in human plasma by UPLC-MS/MS
- (2019) Minou van Seyen et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions
- (2019) Chung-Feng Huang et al. JOURNAL OF INFECTIOUS DISEASES
- Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial
- (2019) Anne Boerekamps et al. Lancet Gastroenterology & Hepatology
- Identification and characterization of latent classes based on drug use among men who have sex with men at risk of sexually transmitted infections in Amsterdam, the Netherlands
- (2019) R. C. A. Achterbergh et al. ADDICTION
- OUP accepted manuscript
- (2018) CLINICAL INFECTIOUS DISEASES
- Should we treat acute hepatitis C? A decision and cost-effectiveness analysis
- (2018) Emily D. Bethea et al. HEPATOLOGY
- The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection
- (2018) Stefan Zeuzem et al. JOURNAL OF GASTROENTEROLOGY
- High efficacy and safety of grazoprevir and elbasvir for 8 weeks in treatment-naive, non-severe fibrosis HCV GT1b-infected patients: Interim Results of the STREAGER Study
- (2018) A. Abergel et al. JOURNAL OF HEPATOLOGY
- EASL Recommendations on Treatment of Hepatitis C 2018
- (2018) Jean-Michel Pawlotsky et al. JOURNAL OF HEPATOLOGY
- Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection
- (2018) M. Martinello et al. JOURNAL OF VIRAL HEPATITIS
- Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis
- (2018) Tarik Asselah et al. LIVER INTERNATIONAL
- Interim analysis of a 3-year follow-up study of NS5A and NS3 resistance-associated substitutions after treatment with grazoprevir-containing regimens in participants with chronic HCV infection
- (2018) Frederick Lahser et al. ANTIVIRAL THERAPY
- Ledipasvir and Sofosbuvir in the Treatment of Early Hepatitis C Virus Infection in HIV-infected Men
- (2018) Paari M Palaniswami et al. Open Forum Infectious Diseases
- The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: An integrated analysis
- (2018) Lawrence Serfaty et al. JOURNAL OF VIRAL HEPATITIS
- Patient-reported outcomes in individuals with hepatitis C virus infection treated with elbasvir/grazoprevir
- (2018) Xinyi Ng et al. Patient Preference and Adherence
- Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection
- (2017) Paul Kwo et al. GASTROENTEROLOGY
- Behavioural, not biological, factors drive the HCV epidemic among HIV-positive MSM: HCV and HIV modelling analysis including HCV treatment-as-prevention impact
- (2017) Louis MacGregor et al. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
- Lack of decline in hepatitis C virus incidence among HIV-positive men who have sex with men during 1990–2014
- (2017) Daniela Katinka van Santen et al. JOURNAL OF HEPATOLOGY
- Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen
- (2016) Christophe Hézode et al. HEPATOLOGY
- Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection
- (2016) Marianne Martinello et al. Open Forum Infectious Diseases
- The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: a study of health-related quality of life
- (2015) Z. M. Younossi et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection
- (2015) Stefan Zeuzem et al. ANNALS OF INTERNAL MEDICINE
- Hepatitis C Virus RNA Levels During Interferon-Free Combination Direct-Acting Antiviral Treatment in Registrational Trials: Table 1.
- (2015) Patrick R. Harrington et al. CLINICAL INFECTIOUS DISEASES
- Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial
- (2015) Mark Sulkowski et al. LANCET
- Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial
- (2015) Jürgen K Rockstroh et al. Lancet HIV
- Evidence of a Large, International Network of HCV Transmission in HIV-Positive Men Who Have Sex With Men
- (2009) Thijis van de Laar et al. GASTROENTEROLOGY
- A systematic review of mental disorder, suicide, and deliberate self harm in lesbian, gay and bisexual people
- (2008) Michael King et al. BMC Psychiatry
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started